Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Trident Lifeline Ltd (543616)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543616 NSE: Pharmaceuticals & Drugs | Small Cap | Trident Lifeline Share Price
₹418 1.00 (0.24%)
As on 04-Nov'26 16:59
Trident Lifeline Ltd (543616)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543616 NSE: Pharmaceuticals & Drugs | Small Cap | Trident Lifeline Share Price
₹418 1.00 (0.24%)
As on 04-Nov'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹500 Cr.
Current Price
₹418
52-Week Low / High
₹230 / 442
TTM EPS
₹15.9
TTM Sales
₹129 Cr.
Book Value per Share
₹90.1
P/E Ratio
26.24
Lower than its 5-year historical median
Industry PE
52.9
Price to Book (P/B)
4.63
Higher than its 5-year historical median
Price to Sales (P/S)
3.87
Lower than its 5-year historical median
EV/EBITDA
15.17
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
24.83%
Outperforms industry median
Return on Capital Employed (ROCE)
22.71%
Outperforms industry median
Return on Assets (ROA)
9.92%
Outperforms industry median
Operating Profit Margin
21.8%
Outperforms industry median
Net Profit Margin
14.97%
Outperforms industry median
Gross Profit Margin
25.8%
Outperforms industry median
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
50.29%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
87.28%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
84.18%
Asset Quality
Promoter Holding
62.46%
Pledged shares (%) of Promoter's holding (%)
11.29%
Reserves
₹99 Cr.
Equity
₹12 Cr.
Face Value
₹10
All Time Low / High
₹102.75 / 442.00
Check Before You Invest
Quality
Not GoodValuation
Somewhat OvervaluedCheck Valuation charts
Price Trend
Weak
Is Trident Lifeline Ltd a good quality company?
Trident Lifeline Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Trident Lifeline Ltd performance compare with that of its Peers?
Revenue growth of Trident Lifeline Ltd vs industry peers?
Trident Lifeline Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 0.00%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Trident Lifeline Ltd?
Promoters hold 62.46% of the Trident Lifeline Ltd, with 11.29% of their stake pledged, indicating high pledge risk.
Stock return of Trident Lifeline Ltd over the last decade?
Over the last 3 year(s), the stock has delivered a CAGR of 29.59% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Trident Lifeline Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -9.1% | 33.7% | 55.1% | 25.1% | 19.1% | 27.7% | 26.1% | - |
| Value Creation Index ⓘ | NA | 1.4 | 2.9 | 0.8 | 0.4 | 1.0 | 0.9 | - |
Growth Parameters ⓘ |
||||||||
| Sales ⓘ | 4.9 | 9.6 | 21.8 | 31.7 | 44.7 | 67.8 | 102 | 102 |
| Sales YoY Gr. | - | 95.1% | 126.3% | 45.6% | 40.9% | 51.9% | 50.3% | - |
| Adj EPS ⓘ | -2.6 | 1.2 | 4.9 | 5.1 | 6 | 11.1 | 14.4 | 15.1 |
| YoY Gr. | - | NA | 314.5% | 5.2% | 18.2% | 84.6% | 29.2% | - |
| BVPS (₹) ⓘ | -9.7 | -0.9 | 6 | 39.7 | 45.8 | 57.1 | 79.9 | 90.3 |
| Adj Net Profit ⓘ | -0.8 | 0.6 | 3.9 | 5.9 | 6.9 | 12.8 | 17.2 | 18 |
| Cash Flow from Ops. ⓘ | -0.6 | 1.5 | -0.2 | -16.6 | 0.9 | 2 | 7.9 | - |
| Debt/CF from Ops. ⓘ | -10.9 | 3.1 | -12.8 | -0.2 | 6.9 | 7.6 | 3.1 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 60.3% | 47.6% | 50.3% | ||||
| Adj EPS ⓘ | NA | 65.2% | 41.3% | 29.2% | ||||
| BVPSⓘ | NA | NA | 26.3% | 39.8% | ||||
| Share Price | - | - | 29.6% | 39.3% | ||||
Key Financial Parameters ⓘ
| Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 27.1 | -33.6 | 180.3 | 23.3 | 14.1 | 21.6 | 20.8 | 17.7 |
| Op. Profit Mgn % ⓘ | -5.5 | 13 | 12.4 | 19.8 | 19.9 | 26.1 | 23.9 | 26.8 |
| Net Profit Mgn % ⓘ | -16.5 | 6.1 | 17.8 | 18.5 | 15.5 | 18.9 | 16.8 | 17.8 |
| Debt to Equity ⓘ | -2.2 | -9.6 | 0.5 | 0.1 | 0.1 | 0.2 | 0.3 | 0.3 |
| Working Cap Days ⓘ | 0 | 223 | 164 | 267 | 355 | 326 | 316 | 158 |
| Cash Conv. Cycle ⓘ | 0 | 30 | 33 | 95 | 118 | 102 | 113 | 106 |
Valuation of Trident Lifeline - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 3.46 | 3.46 | 3.46 | 3.43 | 6.77 | 6.90 | 6.93 | 11.29 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|
| Sales | 22 | 32 | 45 | 87 | 129 |
| Operating Expenses ⓘ + | 19 | 25 | 36 | 72 | 101 |
| Operating Profit ⓘ | 3 | 6 | 8 | 15 | 28 |
| Operating Profit Margin (%) | 12.4% | 19.8% | 18.5% | 17.3% | 21.8% |
| Other Income ⓘ + | 1 | 1 | 2 | 8 | 10 |
| Interest ⓘ | 0 | 0 | 1 | 4 | 5 |
| Depreciation ⓘ | 0 | 0 | 1 | 5 | 6 |
| Profit Before Tax ⓘ | 3 | 7 | 9 | 14 | 27 |
| Tax ⓘ | -1 | 1 | 3 | 3 | 8 |
| Profit After Tax | 4 | 6 | 6 | 10 | 19 |
| PAT Margin (%) | 18.1% | 19.0% | 13.3% | 12.1% | 15.0% |
| Adjusted EPS (₹) | 4.9 | 5.2 | 5.5 | 10.2 | 16.0 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 5 | 46 | 52 | 64 | 97 | ||||||
| Debt + | 2 | 6 | 17 | 49 | 66 | ||||||
| Minority Interest | 0 | 1 | 1 | 5 | 7 | ||||||
| Trade Payables | 5 | 5 | 8 | 15 | 38 | ||||||
| Others Liabilities ⓘ | 1 | 4 | 11 | 22 | 25 | ||||||
| Total Liabilities ⓘ | 13 | 62 | 88 | 155 | 234 | ||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 1 | 3 | 21 | 44 | 61 | ||||||
| CWIP ⓘ | 0 | 5 | 4 | 2 | 18 | ||||||
| Investments ⓘ | 0 | 3 | 4 | 11 | 8 | ||||||
| Inventories | 4 | 7 | 13 | 28 | 36 | ||||||
| Trade Receivables | 5 | 12 | 13 | 28 | 74 | ||||||
| Cash Equivalents | 0 | 14 | 7 | 2 | 4 | ||||||
| Others Assets ⓘ | 3 | 18 | 26 | 41 | 33 | ||||||
| Total Assets ⓘ | 13 | 62 | 88 | 155 | 234 | ||||||
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -0 | -19 | 2 | -4 | 5 |
| Cash Flow From Investing Activity ⓘ + | -0 | -10 | -20 | -14 | -37 |
| Cash Flow From Financing Activity ⓘ + | 1 | 42 | 11 | 14 | 34 |
| Net Cash Flow ⓘ | 0 | 14 | -7 | -4 | 2 |
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 83.23 | 24.21 | 12.52 | 18.78 | 24.83 | |||||
| ROCE (%) | 43.21 | 23.6 | 15.32 | 19.17 | 22.71 | |||||
| Asset Turnover Ratio | 1.69 | 0.84 | 0.6 | 0.72 | 0.66 | |||||
| PAT to CFO Conversion(x) | -0 | -3.17 | 0.33 | -0.4 | 0.26 | |||||
| Working Capital Days | ||||||||||
| Receivable Days | 83.30 | 98.20 | 104.40 | 86.30 | 143.30 | |||||
| Inventory Days | 62.20 | 62.70 | 80.80 | 85.70 | 91.50 | |||||
| Payable Days | 177.30 | 111.70 | 90.80 | 110.90 | 140.20 | |||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Annual reports
No annual reports available.
Concalls
No concalls available.
Trident Lifeline Ltd FAQs
The current trading price of Trident Lifeline on 04-Nov-2026 16:59 is ₹418.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Nov-2026 the market cap of Trident Lifeline stood at ₹499.6 Cr
The latest P/E ratio of Trident Lifeline as of 03-Nov-2026 is 27.61.
The latest P/B ratio of Trident Lifeline as of 03-Nov-2026 is 4.62.
The 52-week high of Trident Lifeline is ₹442.0 and the 52-week low is ₹229.9.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Trident Lifeline is ₹102 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Trident Lifeline Ltd is a below average quality company.
The key valuation ratios of Trident Lifeline Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Trident Lifeline Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Trident Lifeline Ltd
The Company was originally incorporated as “Trident Lifeline Private Limited” as a Private Limited Company under the provisions of the Companies Act, 1956 vide Certificate of Incorporation dated January 09, 2014, issued by the Registrar of Companies, Gujarat, Dadra and Nagar Havelli. Subsequently, the Company was converted into a Public Limited Company pursuant to shareholders resolution passed at Extra-ordinary General Meeting of the Company held on June 02, 2022 and the name of the Company was changed to “Trident Lifeline Limited”. A fresh Certificate of Incorporation consequent upon Conversion from Private Limited Company to Public Limited Company dated June 10, 2022 was issued by the Registrar of Companies, Ahmedabad.
Trident Lifeline is engaged in the pharmaceutical business ethical marketing in domestic as well as international market. It is also engaged in distribution of pharmaceutical products through third party distribution network. It offers wide range of pharmaceutical formulations and products manufactured on contract manufacturing under loan lisence. It operates in India as well as African, Latin American and East Indian Countries. It has its presence through registered products or products under registration in countries like Bolivia, Cambodia, Cameroon, Chile, Ghana, Kenya, Myanamar, Nigeria, Peru, Sudan, Tajikistan, Uzbekistan, Venuzela.
The company is engaged in the business of marketing pharmaceutical products. For which it has obtain necessary approvals from FDA for getting the formulations manufacture from contract manufacturers on Loan License or on principle-to-principle basis. It also takes the necessary Trademark approvals & registrations wherever required. Its Pharma business operations are supported by various contract manufacturers having facilities which are approved by FDA/WHO and other relevant authorities. It typically works on contract manufacturing basis or at times purchase order basis, depending upon customer’s requirement, with manufacturer of pharma products. Presently the company operates with one contract manufacturer. The company has maintained relationship with the regular supplier, having FDA and WHO approved plant to supply pharma formulations. These units manufacture tablets, capsules, dry powder, syrup under its own brands.
Business area of the company
The company is engaged in the manufacturing and marketing of quality finished dosages. It is one of the fastest growing pharmaceutical companies in the SME segment providing unprecedented quality of healthcare products. It deals in Capsules, Tablets, Liquid Ointment, Gel, Ice Gel, Mouthwash, Paste, Solution, Suspension, Drypowders and Toothpaste. Its product portfolio comprises of vide range of drugs like Anti Bacterial, Anti Diarrheal, Anti Fungal, Anti Malerial, Anti Diabetic, Dental Cure, Proton Pump Inhibitor, Anti Protozol, Anti Histamine, Anti Hypertensive drugs, Anti Lipidemic Drug, Anti Parasitic, Multivitamin, Multimineral Nyteraceutical and Non-steriodal anti-inflamatory drug (NSAIDS).
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now